Drug information

Savlon First Aid Wash

OTC

Read time: 1 mins

Last updated: 15 Feb 2017

Summary of product characteristics

1. Name of the medicinal product

Savlon® First Aid Wash 0.5% w/v Cutaneous Spray, Solution.

2. Qualitative and quantitative composition

Cetrimide 0.5 % w/v

3. Pharmaceutical form

Cutaneous spray, solution (Cutaneous spray)

4.1. Therapeutic indications

For cuts, grazes, insect bites, minor wounds, spots, minor burns and scalds.

4.2. Posology and method of administration

For topical application.

Adults, children and the elderly

Hold upright and spray from a distance of 2 to 4 inches on the affected area. Spray the affected area two or three times a day.

4.3. Contraindications

Hypersensitivity to any of the ingredients.

4.4. Special warnings and precautions for use

Prolonged and repeated administration may lead to hypersensitivity. Do not use if the skin is weeping or badly inflamed.Avoid contact with the eyes. For external use only.Keep all medicines out of the reach of children.

4.5. Interaction with other medicinal products and other forms of interaction

There are no clinically significant interactions.

4.6. Fertility, pregnancy and lactation

The safety of First Aid Antiseptic Spray during pregnancy and lactation has not been established but it is not considered to constitute a hazard during these periods.

4.7. Effects on ability to drive and use machines

No adverse effects known.

4.8. Undesirable effects

Skin irritation may occasionally occur and hypersensitivity reactions may develop in certain individuals.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9. Overdose

It is unlikely that systemic toxicity will result from the ingestion of First aid Antiseptic Spray, although it may give rise to gastrointestinal irritation. Treatment should be symptomatic.

5.1. Pharmacodynamic properties

Cetrimide is a quaternary ammonium disinfectant having bactericidal activity against both gram-positive and gram-negative organisms.

5.2. Pharmacokinetic properties

None stated.

5.3. Preclinical safety data

Not applicable.

6.1. List of excipients

Sodium citrate

Anhydrous citric acid

Di-Sodium edetate

Purified water

6.2. Incompatibilities

None stated

6.3. Shelf life

36 months

6.4. Special precautions for storage

None stated

6.5. Nature and contents of container

Polythene bottle 100 ml with plastic spray pump of 50 microlitre dosage.

6.6. Special precautions for disposal and other handling

Hold upright and spray from a distance of 2 to 4 inches on the affected area.

7. Marketing authorisation holder

The Boots Company PLC1 Thane Road WestNottingham NG2 3AA Trading as: BCM

8. Marketing authorisation number(s)

PL 00014/0507

9. Date of first authorisation/renewal of the authorisation

11 April 1997

10. Date of revision of the text

22 December 2014

4.1 Therapeutic indications

For cuts, grazes, insect bites, minor wounds, spots, minor burns and scalds.

4.2 Posology and method of administration

For topical application.

Adults, children and the elderly

Hold upright and spray from a distance of 2 to 4 inches on the affected area. Spray the affected area two or three times a day.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

4.5 Interaction with other medicinal products and other forms of interaction

There are no clinically significant interactions.

4.6 Fertility, pregnancy and lactation

The safety of First Aid Antiseptic Spray during pregnancy and lactation has not been established but it is not considered to constitute a hazard during these periods.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

Skin irritation may occasionally occur and hypersensitivity reactions may develop in certain individuals.

Reporting of suspected adverse reactions

Clinical trial

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.

2 mins

Clinical trial

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

To demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess long term efficacy, safety and tolerability of secukinumab.

4 min

Clinical trial

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

This study will evaluate the effects of an experimental (being tested) study drug called apremilast.

2 min

Journal

Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions

Objective: We sought to evaluate the efficacy and patient satisfaction of the deroofing technique for recurrent Hurley I (mild) or II (moderate) graded HS lesions at fixed locations.

1 mins

Journal

Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management

<p>The recognition of the central role of interleukin 17A (IL-17A) in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes.</p>

1 min

Journal

Morbidity in patients with hidradenitis suppurativa

Objectives: To measure the impairment of life quality in patients with HS.

1 min

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).

Savlon First Aid Wash

Summary of product characteristics

4.1 Therapeutic indications

4.2 Posology and method of administration

4.3 Contraindications

4.4 Special warnings and precautions for use

4.5 Interaction with other medicinal products and other forms of interaction

4.6 Fertility, pregnancy and lactation

4.7 Effects on ability to drive and use machines

4.8 Undesirable effects

Drug section

Learning Zones

Disclaimer

Drug Licencing